10x Genomics
TXG | NASDAQ
$54.99
-$3.20 (-5.50%)
At close: Nov 16, 2026, 4:00 PM ET
$54.51
-$0.48 (-0.87%)
After-hours:
Nov 16, 2026, 7:55 PM ET
10x Genomics Company Profile
Company profile explainedCompany Profile
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Key Executives
| Name | Position |
|---|---|
| Serge Saxonov | Co-Founder, Chief Executive Officer & Director |
| Adam S. Taich | Chief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer |
| Michael Schnall-Levin | Founding Scientist & Chief Technology Officer |
| Benjamin J. Hindson | Co-Founder, President, Chief Scientific Officer & Director |
| Cassie Corneau | Manager of Investor Relations & Strategic Finance |
| Jens Durruthy | Associate Director of Product Management |
| Jim Goodrich | Chief of Global Operations |
| Mennah Moustafa | Chief Commercial Officer |
| Randy Wu | General Counsel and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 07, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 24, 2026 | 4 | Filing |
| Sep 24, 2026 | 4 | Filing |
| Sep 11, 2026 | 4 | Filing |
| Sep 08, 2026 | 4 | Filing |
| Sep 08, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 03, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 26, 2026 | 4 | Filing |
| Aug 26, 2026 | 4 | Filing |
10x Genomics
| Country | United States |
| IPO Date | Sep 12, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,178 |
| CEO | Serge Saxonov |
Contact Details
6230 Stoneridge Mall Road Pleasanton,
California 94588-3260 United States
Stock Details
| Ticker Symbol | TXG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001770787 |
| CUSIP Number | 88025U109 |
| ISIN Number | US88025U1097 |
| SIC Code | 3826 |
Recent News
- 4 days ago / zacks.com10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study
- 6 days ago / prnewswire.comShanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform
- 8 days ago / marketbeat.comWhat Torex Gold Resources (TXG) Said on Its Q3 Earnings Call
- 11 days ago / zacks.com10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis
- 11 days ago / zacks.comTXG Q3 Earnings Call Highlights Atera Launch and Raised Outlook
- 11 days ago / marketbeat.comWhat 10x Genomics (TXG) Said on Its Q3 Earnings Call
- 11 days ago / zacks.comCompared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key Metrics
- 11 days ago / seekingalpha.com10x Genomics, Inc. (TXG) Q3 2026 Earnings Call Transcript
- 11 days ago / zacks.com10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates
- 11 days ago / prnewswire.com10x Genomics Reports Third Quarter 2026 Financial Results
Add to Watchlist
Select watchlists to add or remove TXG